SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal

Part Of New Modality Focus

 
• By Jung Won Shin
growth strategy
SK Biopharm To Announce Radiopharma Plans This Year • Source: Shutterstock

More from Deals

More from Business